Blog - Page 1134 of 5707

ThursdayDec 02, 2021 9:30 am

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of…

ThursdayDec 02, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period…

ThursdayDec 02, 2021 9:25 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting in the upcoming Stifel GMP second annual Future of Healthcare Conference. The conference, which is slated for Dec. 8, 2021, will include a presentation by Cybin CEO Doug Drysdale. According to the announcement, Drysdale’s presentation is scheduled to start at 3:30 p.m. ET. Following the presentation, interested viewers can view an archived version of the webcast on Cybin’s investor relations website. Cybin is working to create safe and effective therapeutics for patients to address a multitude of mental health issues. To view the…

ThursdayDec 02, 2021 9:00 am

Marijuana Company of America Inc. (MCOA) Leverages Strategic Partnerships to Facilitate Growth Within the Industry

The global cannabis market was valued at $22.10 billion and is expected to grow at a CAGR of 13.9% by 2026. The growing trend was reflected by Green Wednesday sales MCOA has expanded its interests into Latin America and has strategic partnerships in place, as well as wholly-owned subsidiaries in its portfolio Leadership team has set high standards for the company and plans to leverage the strategic partnerships it has accumulated as a means of facilitating growth for the company within the industry The cannabis industry just celebrated its second-largest holiday of the year – Green Wednesday, the industry’s very…

ThursdayDec 02, 2021 9:00 am

Cannabis Strategic Ventures Inc. (NUGS) Moving Forward to Achieve Vision of Being Top-Tier, Farm-to-Door, Premium Cannabis Company

NUGS “wasting no time” in deploying assets to launch one of California’s top vertical cannabis models Company plans to deploy another new license for establishment of indoor cultivation facility Four licenses provide regulatory backing for a series of major next steps critical to NUGS’ strategy An emerging leader in the U.S. cannabis marketplace, Cannabis Strategic Ventures (OTC: NUGS) is taking key steps forward in its strategic plan to implement a farm-to-sale model (https://ibn.fm/r7DFR). The company is beginning to deploy its newly acquired licenses, including the opening of its first Los-Angeles-based, customer-facing MDRN (Modern) Tree cannabis dispensary. “After securing key licensing,…

WednesdayDec 01, 2021 2:51 pm

QualityStocksNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one of its lead drug candidates. Nanoemulsion is an advanced drug delivery system that offers enhanced stability, fast digestibility, controlled release and protection against degradation. “Specifically, Mydecine is targeting the enhanced bioavailability and controlled capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will…

WednesdayDec 01, 2021 2:43 pm

QualityStocksNewsBreaks – Friendable Inc. (FDBL) Providing Artists, Fans the Best that Music Offers

Friendable (OTC: FDBL), a mobile technology and marketing company, released Fan Pass in July 2020 as a platform for artists to share their work and fans to get a front-row seat to the action from the comfort of their home. Since then, the platform has grown considerably. “During the latter part of 2021, the company’s main focus has been to make the Fan Pass platform more visible and accessible. Now, the company is focusing on moving into 2022, offering artists and fans the best that music offers,” reads a recent article. “Artists who sign up with the Fan Pass platform…

WednesdayDec 01, 2021 2:40 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of comorbidities that include anxiety, depression, poor sleep quality and other conditions. Tryp expects to initiate the study in 2022, subject to a favorable…

WednesdayDec 01, 2021 2:00 pm

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) to Deconsolidate BIGtoken Inc. (FPVD) Following Merger

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has announced that, from this date forward, it will no longer have to consolidate the financials of BIGtoken (OTC: FPVD). On Sept. 27, 2021, BIGtoken, the leading platform for ethically-sourced identity, data and insights creation and media activation, and BritePool Inc., a leading identity verification company for advertisers and publishers, entered into an agreement and plan of merger in an all-stock transaction. Upon completion of the union, SRAX is no longer obligated to consolidate BIGtoken into its financials.…

Site Search

Company Search